Loading data for CLDX — first visit, this takes a few seconds.
Celldex Therapeutics Inc. (CLDX)
NasdaqCM: CLDX
· Real-Time Price · USD
41.70
-0.09 (-0.22%)
At close: Aug 20, 2026, 2:50 PM
Celldex Therapeutics Inc. (CLDX) Stock Price, Analysis & Data
-0.22% (1D)
No data available
| Bid | 35.58 |
| Market Cap | 3.15B |
| Revenue (ttm) | 158K |
| Net Income (ttm) | -300.55M |
| Beta | 0.84 |
| EPS (ttm) | -4.35 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.63 |
| P/B (ttm) | 4.40 |
| P/S (ttm) | 19923.49 |
| Earnings Date | Nov 9, 2026 |
| Ask | 47.63 |
| Volume | 1,323,368 |
| Avg. Volume (20D) | 1,032,000 |
| Open | 42.51 |
| Previous Close | 41.79 |
| Day's Range | 41.33 - 43.20 |
| 52-Week Range | 20.37 - 45.14 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that spe...
Industry Biotechnology
Sector Healthcare
IPO Date May 15, 1986
Employees 198
Stock Exchange NasdaqCM
Ticker Symbol CLDX
Website https://www.celldex.com
Financial Performance
In 2025, Celldex Therapeutics's revenue was 1.54M, a decrease of -77.99% compared to the previous year's 7.02M. Earnings were -258.76M, an increase of 63.91%.
Financial StatementsEarnings Surprise
Celldex Therapeutics has released their quarterly earnings on Aug 6, 2026:
Celldex Therapeutics Inc. is scheduled to release its earnings on Nov 9, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2